Search research articles
Contact Us
Filters
Showing results (21-30 of 83) with videos related to
Page
of 9
Sort By:
British Journal of Haematology
|
February 7, 2024
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey
Darcy R Flora, Susan K Parsons, Nicholas Liu, et al.
Oncotarget
|
July 11, 2018
Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis
Dai Chihara, Nathan H Fowler, Yasuhiro Oki, et al.
JCO Oncology Practice
|
March 22, 2023
Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study
Susan K Parsons, Kristina S Yu, Nicholas Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2011
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies
Michelle A Fanale, Andres Forero-Torres, Joseph D Rosenblatt, et al.
Journal of Cardiac Failure
|
April 16, 2016
The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study
Daniel J Lenihan, Patrick L Stevens, Mona Massey, et al.
Ophthalmic Plastic and Reconstructive Surgery
|
August 21, 2018
Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma
Oded Sagiv, Sudip D Thakar, John T Manning, et al.
The Lancet. Haematology
|
December 22, 2015
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
Chan Yoon Cheah, David Belada, Michelle A Fanale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study
Michelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
British Journal of Haematology
|
March 2, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma
Tamer Khashab, Fredrick Hagemeister, Jorge E Romaguera, et al.
Leukemia & Lymphoma
|
December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Ajay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 83) with videos related to
Sort By:
Page
of 9
British Journal of Haematology
|
February 7, 2024
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey
Darcy R Flora, Susan K Parsons, Nicholas Liu, et al.
Oncotarget
|
July 11, 2018
Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis
Dai Chihara, Nathan H Fowler, Yasuhiro Oki, et al.
JCO Oncology Practice
|
March 22, 2023
Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study
Susan K Parsons, Kristina S Yu, Nicholas Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2011
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies
Michelle A Fanale, Andres Forero-Torres, Joseph D Rosenblatt, et al.
Journal of Cardiac Failure
|
April 16, 2016
The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study
Daniel J Lenihan, Patrick L Stevens, Mona Massey, et al.
Ophthalmic Plastic and Reconstructive Surgery
|
August 21, 2018
Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma
Oded Sagiv, Sudip D Thakar, John T Manning, et al.
The Lancet. Haematology
|
December 22, 2015
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
Chan Yoon Cheah, David Belada, Michelle A Fanale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study
Michelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
British Journal of Haematology
|
March 2, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma
Tamer Khashab, Fredrick Hagemeister, Jorge E Romaguera, et al.
Leukemia & Lymphoma
|
December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Ajay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Page
of 9